Chiesi's Commercial Hopes In US Hit By FDA Letter
Protalix-Partnered Fabry Drug Turned Down By Agency
Shares in Protalix sank more than 30% after the company received a complete response letter from US regulators for pegunigalsidase alfa for Fabry disease. No inspection of the company's manufacturing plant in Israel appears to be the main sticking point.
